St. Jude Medical Broadens Treatment Options for Patients Suffering Movement Disorders with the European Launch of New Deep Br...
June 16 2016 - 8:00AM
Business Wire
The Infinity™ Deep Brain Stimulation System and directional lead
provides patients battling Parkinson’s disease, tremor and dystonia
more patient-centric, intuitive technology options
St. Jude Medical, Inc. (NYSE:STJ), a global medical device
company, today announced the European launch of the St. Jude
Medical Infinity™ Deep Brain Stimulation (DBS) System and
directional DBS lead. The system, which received CE Mark approval
late in 2015, will support the treatment of patients with the three
most common movement disorders in the world: Parkinson’s disease,
tremor and dystonia, a disorder which causes involuntary muscle
contractions.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160616005419/en/
The St. Jude Medical Infinity DBS system
is the only upgradeable DBS system available to patients battling
movement disorders. (Photo: St. Jude Medical)
Movement disorders are neurologic conditions caused by a
communication breakdown throughout the central nervous system that
can result in a debilitating loss of muscle control, involuntary
movement and reduced coordination. There are currently no proven
cures for movement disorders, which means treatment options focus
on alleviating symptoms to improve quality of life. St. Jude
Medical designed the Infinity system to improve the experience of
patients who rely on DBS therapy to manage their symptoms. The
company also developed the St. Jude Medical directional lead to
help physicians more accurately tailor DBS therapy to their
patient’s specific needs while reducing side effects.
The first physician to implant the new Infinity system and the
St. Jude Medical directional lead was Prof. Jan Vesper, a professor
of functional neurosurgery and stereotaxy at the University
Hospital in Düsseldorf, Germany, and president of the German
Neuromodulation Society.
“The Infinity system is the first DBS system I’ve encountered
that adjusts to the patient’s individual needs, rather than forcing
the patient to adjust to the system,” said Prof. Vesper. “Offering
my patients a DBS system with exceptional ease of use and smooth
manageability is an exciting step in the treatment of debilitating
movement disorders.”
A DBS system, like the St. Jude Medical Infinity DBS system,
delivers mild electrical pulses to specific targets in the brain to
stimulate the structures involved in motor control. With the launch
of the Infinity system, St. Jude Medical aims to empower physicians
to more accurately deliver stimulation with a DBS system. The new
St. Jude Medical directional lead can deliver stimulation more
precisely through eight independent electrodes that allow
physicians to specifically direct current to targeted structures
and areas of the brain. This advance will allow physicians to
tailor the therapy to a patient’s specific needs while avoiding
unnecessary stimulation to areas that may create side effects.
The Infinity system also offers new, distinct patient
advantages. For patient comfort, the system is available in two
different sizes, offers a maintenance-free and long-lasting
recharge-free system, and uses Bluetooth® wireless technology and
Apple™ digital devices for its patient controller and physician
programmers. In addition, the St. Jude Medical Infinity system is
also upgradeable, which provides patients the potential to access
new therapy advances as they’re approved without the need for
repeat surgery.
“The Infinity DBS system and directional lead design was
designed to meet the needs of physicians who confirmed that they
needed a system that prioritized improved stimulation targeting,
device longevity and improved patient ease of use,” said Dr. Allen
Burton, medical director of neuromodulation and vice president of
medical affairs at St. Jude Medical. “The Infinity DBS system is
our answer for these previously unmet needs, demonstrating St. Jude
Medical’s commitment to patient-centric solutions that help
alleviate the debilitating effects of movement disorders.”
For more information about St. Jude Medical’s focus on the
treatment of movement disorders, visit the St. Jude Medical
Movement Disorder Media Kit or the St. Jude Medical PULSE Blog.
Note: Apple, is a trademark of Apple, Inc. Bluetooth is a
trademark of Bluetooth SIG, Inc.
About St. Jude Medical
St. Jude Medical is a leading global medical device manufacturer
and is dedicated to transforming the treatment of some of the
world's most expensive epidemic diseases. The company does this by
developing cost-effective medical technologies that save and
improve lives of patients around the world. Headquartered in St.
Paul, Minn., St. Jude Medical employs approximately 18,000 people
worldwide and has five major areas of focus that include heart
failure, atrial fibrillation, neuromodulation, traditional cardiac
rhythm management and cardiovascular. For more information, please
visit sjm.com or follow us on Twitter @SJM_Media.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made
by the Company are based upon management’s current expectations and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control
and the risk factors and other cautionary statements described in
the Company’s filings with the SEC, including those described in
the Risk Factors and Cautionary Statements sections of the
Company’s Annual Report on Form 10-K for the fiscal year ended
January 2, 2016 and Quarterly Report on Form 10-Q for the fiscal
quarter ended April 2, 2016. The Company does not intend to update
these statements and undertakes no duty to any person to provide
any such update under any circumstance.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160616005419/en/
St. Jude Medical, Inc.Investor RelationsJ.C. Weigelt,
651-756-4347jweigelt@sjm.comorMedia RelationsLaurel Hood,
651-756-2853LHood02@sjm.com
SJM (NYSE:STJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Apr 2023 to Apr 2024